posted
MedWatch - The FDA Safety Information and Adverse Event Reporting Program
Hanford Pharmaceuticals and FDA notified healthcare professionals about the recall of four lots (379,975 vials) of Cefazolin for Injection, USP, 1 g/10 mL vials, an antibiotic used in a hospital environment to treat skin and skin structure, respiratory and other infections.The product was distributed by Sandoz, Inc. of Broomfield, CO and Watson Pharmaceuticals, Inc. of Corona, CA. Certain lots of the active ingredient used to manufacture the product have been shown to contain microbial contamination (Bacillus pumilus, Staphylococcus hominis, Propionibacterium acnes, or Micrococcus luteus) which may pose a serious or life-threatening risk for some patients. Hospitals, clinics, and users should stop using the affected lots immediately.
Read the complete MedWatch 2006 Safety summary, including a link to the firm's press release, at:
Thank you for using MedWatch as a trusted source for timely safety information on drugs and other medical products regulated by the U.S. Food and Drug Administration. If you find this e-mail notification helpful, please consider telling colleagues and friends about MedWatch. They can learn more about us and subscribe/unsubscribe to the e-list at the MedWatch homepage, http://www.fda.gov/medwatch or by going directly to https://list.nih.gov/cgi-bin/wa?SUBED1=medwatch&A=1
This is an automated message delivery system -- replying to this message will not reach MedWatch staff. If you have comments or questions about MedWatch or this e-mail, please contact us through our comments & feedback web page, http://www.fda.gov/medwatch/feedback.htmPosts: 31 | From Arlington, VA USA | Registered: Aug 2005
| IP: Logged |
The Lyme Disease Network is a non-profit organization funded by individual donations. If you would like to support the Network and the LymeNet system of Web services, please send your donations to:
The
Lyme Disease Network of New Jersey 907 Pebble Creek Court,
Pennington,
NJ08534USA http://www.lymenet.org/